Subscribe
Pet Health & Wellness
13 min read

Deven Vespi | Advisor, DRV Advisory

Clinically proven has no shared definition in pet, yet it now shapes deals as much as labels. Deven Vespi learned the trade in FDA-regulated animal health, and she explains how to check a study before you trust it or build a deal on it. She covers sample sizes, dosing gaps, why brands get blindsided by their own research, and how long published data stays an edge.

Written by
Roy Ben-Tzvi
Published on
November 19, 2026
Deven Vespi, Advisor of DRV Advisory
Deven Vespi
Deven Vespi

“Clinically proven” has moved beyond the label and into the deal room. Scientific proof now shapes consumer trust, and more and more it shapes investment, M&A, and partnership talks too. But the pet industry still has no shared definition of the phrase, and none of the existing standards bodies test whether a product actually works.

Deven Vespi learned the business under strict rules. In FDA-regulated animal health, you can’t say a word beyond what a peer-reviewed, published study shows. After earning her MBA, she moved to the health additives side of animal nutrition and found a market where that kind of research existed but wasn’t the norm.

She is now pursuing a Doctorate of Business Administration at Paris School of Business focused on negotiation, and advises a few startups on go-to-market strategy. Her published writing has mostly focused on dealmaking. Here, she turns to the science.

We asked her how to tell real proof from good marketing. In this interview, she covers:

  • The first thing to check in any study, and why some “clinically proven” claims fall apart on it
  • The kind of claim that should make a US buyer suspicious, and why the rules differ in the UK
  • A dosing gap she has seen in formulas around the world, even when the right ingredient is on the panel
  • The internal mistake that blindsides brands when their own study gets published
  • A bill in Congress that could change who has a reason to pay for research
  • Why published data gives you leverage at the table, and why that leverage expires

Plus, why she sees an opportunity beyond premium pet: the animals around the world that barely get basic care.

Subscribe to newsletter

Join our newsletter to stay up to date on features and releases.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

By clicking Sign Up you're confirming that you agree with our Terms and Conditions.

Pro
Keep Reading

Other Interviews

More conversations with founders, operators, and investors building the future of pet care.

Learn more
Meet the Founders: 3 Startups Shaping the Future of Pet Health
Pet Health & Wellness
10 min read

Meet the Founders: 3 Startups Shaping the Future of Pet Health

Pawsible Ventures took seven of more than 130 applicants into its second cohort. Three of them work very different corners of pet health. Nicole Shlomof and Gila Leibovitch of Pawp Water sell functional water to owners who already fill the bowl, Andria Beal of EpiPaws turned dolphin epigenetics research into biological-age tests for dogs and cats, and Elliot Greenwood of ChckVet sells software to vet practices that resist new tech.

Learn more
Learn more
Elizabeth Iorns | Co-Founder & CEO, Familiar Therapeutics
Pet Health & Wellness
17 min read

Elizabeth Iorns | Co-Founder & CEO, Familiar Therapeutics

Elizabeth Iorns lost her French Bulldog to a brain tumor that a published canine study suggested could be treated, but no company had taken the drug forward for dogs. Now she and Science Exchange co-founder Dan Knox license the companion animal rights to human drugs at Familiar Therapeutics: 13 programs and $5 million raised in five months, plus a pitch to pharma that pet trials validate targets faster than phase two.

Learn more
Learn more
Brian Cheng | Co-Founder, HOLY CAP
Pet Food & CPG
11 min read

Brian Cheng | Co-Founder, HOLY CAP

HOLY CAP launched in Hong Kong in 2022 selling functional mushroom powders and learned fast that pet owners will not measure another supplement into the bowl. Co-founder Brian Cheng explains the pivot to lickable Squeezees, why in-person sampling beats Amazon at this stage, the operating cost of 14 SKUs split across dogs and cats, and the plan to become a complete-diet brand.

Learn more
View all interviews